Public Policy Resources

Share

Photo of ACS CAN Volunteers at Advocacy Event to Support Cancer Research Funding

Research, Funding and Drug Development

Improvements in outcomes for cancer patients require continued research and innovation.  ACS CAN advocates for robust federal funding for cancer research, as well as research and drug approval policies that accelerate the development of new treatments while still ensuring patient safety.

Research, Funding and Drug Development Resources:

Expanded Access Principles

May 2, 2017

Expanded access inovolves accessing unapproved therapies outside of clinical trials.  This process has been in existience since the late 1980s, and currently there have been calls to change the process.

Letter to Congress Requesting Action on LDT Oversight

January 24, 2017

Molecular tests are critical to safe, effective care for cancer patients, yet the oversight system for laboratory developed tests is in need of updating.  This letter, co-signed by 33 organizations, request that Congress act to ensure appropriate diagnostic oversight. 

Childhood Cancer Research Landscape Report

September 27, 2016

This report examines the drug development landscape for childhood cancer, identifying scientific, logistical, economic and ethical challenges that are unique to pediatric cancer drug development. 

Immunotherapy--How it can Help in the Fight Against Cancer

October 5, 2015

Immunotherapy is a growing area of cancer drug development, and this educational brochure explains in lay language how immunotherapies for cancer work.

ACS CAN Comments on FDA’s Proposed LDT Oversight Framework

February 2, 2015

This letter provides feedback on FDA's proposal to extend oversight to laboratory developed tests (LDTs).  The letter expressed ACS CAN's general support for this change.

Comments on proposed changes to Common Rule protecting research subjects Oct 2011

October 26, 2011

This joint ACS/ ACS CAN letter provided feedback to proposed changes in the "Common Rule," which outlines the ethical requirements for conducting federally funded research with humans. 

  •